The addition of nab-paclitaxel to gemcitabine did not significantly extend DFS per independent reviewer assessment among patients with surgically resected pancreatic cancer, according to results of the randomized phase 3 APACT trial presented at ASCO Annual Meeting.
However, the combination appeared to improve OS and DFS according to investigator assessment compared with gemcitabine alone at this interim analysis, and it may be a treatment option for select patients. Read more . . .